Last updated: February 20, 2026
Savaysa (generic name: edoxaban) is an oral anticoagulant marketed by Daiichi Sankyo. It is used to prevent stroke and systemic embolism in non-valvular atrial fibrillation and treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).
Manufacturing and Supply Sources
Daiichi Sankyo
- Primary manufacturer: Daiichi Sankyo, headquartered in Japan, develops and produces Savaysa globally.
- Supply chain: The company operates multiple manufacturing facilities across Japan, the United States, and Europe.
Contract Manufacturing Organizations (CMOs)
- Daiichi Sankyo engages several CMOs for formulation and finished product manufacturing to meet global demand.
- Key regions for contract manufacturing include Asia and Europe, where CMOs adhere to Good Manufacturing Practice (GMP) standards.
Raw Material Suppliers
- Edoxaban's chemical synthesis involves specialized intermediates requiring sourcing from global chemical suppliers.
- Critical raw materials come primarily from Asia (Japan, China, India), with some inputs sourced from Europe and the United States.
- Suppliers of active pharmaceutical ingredients (API) often include:
- Daicel Corporation (Japan)
- Mitsubishi Gas Chemicals (Japan)
- Other specialty chemical providers in China and India
Distribution Channels
- Daiichi Sankyo manages logistics, partnering with global distribution networks, including:
- Major wholesalers (McKesson, Cardinal Health, and AmerisourceBergen)
- International logistics firms (DHL, FedEx) for timely global delivery
Key Regulatory Approvals and Market Access
- Regulatory status: Approved by the FDA (U.S.), EMA (Europe), and other agencies.
- Market exclusivity: Patent protection in major markets extends through 2025, with potential for generic entry afterward.
- Supply constraints: Post-approval manufacturing scaling has occasionally caused shortages, mitigated through diversified sourcing and manufacturing partnerships.
Competitive Landscape and Supply Security
- Generic manufacturers are preparing for patent expiry, aiming to produce edoxaban or biosimilar compounds.
- Daiichi Sankyo's reliance on its manufacturing network minimizes supply disruptions; however, geopolitical and regulatory factors influence raw material and API sourcing.
Summary
Daiichi Sankyo remains the principal supplier for Savaysa, leveraging vertical integration and CMOs to fulfill global demand. Raw materials primarily originate from Asia, with distribution through extensive wholesale networks.
Key Takeaways
- Daiichi Sankyo is the primary manufacturer and distributor.
- A network of CMOs supplements in-house production.
- Critical raw materials largely come from Asia, including Japan, China, and India.
- Supply chains are diversified but susceptible to geopolitical and regulatory risks.
- Patent protection extends until 2025, after which generic competition may increase supply options.
FAQs
Q1: Does Daiichi Sankyo license Savaysa manufacturing to other companies?
A1: No, Daiichi Sankyo retains the primary manufacturing rights but uses CMOs for scale-up and specific markets.
Q2: Are there regional variations in Savaysa supplies?
A2: Yes, regional manufacturing facilities and partnership agreements lead to slight variations in supply, but global distribution aims for consistency.
Q3: What are the main raw materials used for edoxaban synthesis?
A3: Specialized intermediates sourced from Asian chemical suppliers, including key components produced by Daicel Corporation and Mitsubishi Gas Chemicals.
Q4: How might patent expiration affect the supply landscape?
A4: Post-2025, generic manufacturers are expected to enter the market, increasing supply but potentially impacting pricing and manufacturing practices.
Q5: Are there known supply chain disruptions for Savaysa?
A5: Occasional shortages occurred due to manufacturing scaling; efforts are ongoing to stabilize supply via diversified sources and increased capacity.
References
[1] Daiichi Sankyo. (2023). Savaysa (edoxaban) product information.
[2] U.S. Food and Drug Administration. (2022). Edoxaban (Savaysa) approval and patent info.
[3] European Medicines Agency. (2023). Regulatory status of edoxaban.
[4] MarketResearch.com. (2022). Global anticoagulant drug manufacturing landscape.
